Connect Biopharma

CNTB Lead: Phase 2 4 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-31

Catalyst timeline

Rademikibart atopic dermatitis China decision2H 2026Rademikibart atopic dermatitis China decision, 2H 2026, material
Rademikibart FDA feedback4Q 2026Rademikibart FDA feedback, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

rademikibart

CBP-201

Protein Target: IL-4Rα

Asthma Phase 2 subcutaneous
Asthma Phase 2 intravenous
Chronic Obstructive Pulmonary Disease Phase 2 subcutaneous
Chronic Obstructive Pulmonary Disease Phase 2 intravenous

Discontinued (1)

rademikibart — Atopic Dermatitis · Connect has decided to not currently pursue further development of rademikibart for AD

Biotech Distilled coverage (4)

2026-09-30 UPDATE: Connect Biopharma (CNTB) - The Mirror Image ★ Distilled Pro
2026-09-16 UPDATE: Connect Biopharma (CNTB) - The Trial Failed. The Drug Might Not Have. 🔒 Paid
2026-08-13 UPDATE: Connect Biopharma (CNTB) - The Clock Is Set, The Cushion Is Gone 🔒 Paid
2026-06-08 Connect Biopharma (CNTB) - Scientific Deep Dive for Rademikibart and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.